Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp T.IGX

Alternate Symbol(s):  IGXT

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

IntelGenx Announces Government of Canada Funding for CNS VersaFilm(TM) Project

GlobeNewswire April 30, 2014

IntelGenx and RedHill Biopharma Announce Commencement of a Bioavailability Study With Anti-Migraine VersaFilm(TM) Product to Support European Marketing Application Planned for Q3/2014

GlobeNewswire April 28, 2014

RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study With RHB-103 (Migraine) to Support European Marketing Application Planned for Q3/2014

GlobeNewswire April 28, 2014

CytoSorbents Corp. Expands Its Product Distribution to Include the Middle East

Accesswire April 25, 2014

IntelGenx and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product

Newsfile April 24, 2014

RedHill Biopharma and IntelGenx Provide an Update on FDA's Ongoing Review of the NDA for RHB-103 Oral Migraine Film

GlobeNewswire April 24, 2014

IntelGenx (V.IGX) obtains further U.S. patent for proprietary drug delivery tech

Stockhouse Editorial April 16, 2014

IntelGenx Announces Receipt of an Additional U.S. Patent Allowance Related to Proprietary Technology

GlobeNewswire April 16, 2014

IntelGenx Announces Receipt of an Additional U.S. Patent Allowance Related To Proprietary Technology

Newsfile April 16, 2014

Apply Market Savvy to Bear Market Debris; Uncover Biotech Treasures: Cleland and Ireland

Equities.com March 24, 2014

IntelGenx Reports 2013 Annual Results and Provides Corporate Development Update

GlobeNewswire March 11, 2014

IntelGenx Reports 2013 Annual Results and Provides Corporate Development Update

Newsfile March 11, 2014

IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines

GlobeNewswire March 3, 2014

IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines

Newsfile March 3, 2014

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film

GlobeNewswire March 3, 2014

IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology

Newsfile February 26, 2014

IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology

GlobeNewswire February 26, 2014

IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product

GlobeNewswire February 24, 2014

IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product

Newsfile February 24, 2014

TrendingWallStreet.com Reports Market Analysis on DF, ATEC, NPWZ, and IGXT

Accesswire February 12, 2014